Corium International, Inc. (NASDAQ:CORI) has been given a $10.00 price target by stock analysts at Jefferies Group LLC in a note issued to investors on Sunday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 5.04% from the company’s previous close.
A number of other brokerages have also commented on CORI. Zacks Investment Research upgraded Corium International from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, October 3rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $12.00 target price on shares of Corium International in a research report on Wednesday, September 27th. HC Wainwright began coverage on Corium International in a research report on Tuesday, September 26th. They issued a “buy” rating and a $15.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $13.00 target price on shares of Corium International in a research report on Sunday, September 17th. Finally, WBB Securities upgraded Corium International to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday, July 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $13.00.
Corium International (CORI) opened at 9.52 on Friday. The stock has a 50 day moving average of $10.32 and a 200 day moving average of $7.94. The company’s market cap is $340.26 million. Corium International has a 52 week low of $2.67 and a 52 week high of $11.37.
Corium International (NASDAQ:CORI) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.13). The firm had revenue of $8.11 million during the quarter, compared to analysts’ expectations of $8.71 million. Corium International had a negative net margin of 145.60% and a negative return on equity of 673.17%. Equities research analysts predict that Corium International will post ($1.70) EPS for the current fiscal year.
In other Corium International news, major shareholder Healthcare Master Fun Broadfin sold 218,100 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $11.01, for a total value of $2,401,281.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Parminder Singh sold 30,415 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $7.59, for a total value of $230,849.85. Following the completion of the sale, the insider now owns 30,762 shares in the company, valued at approximately $233,483.58. The disclosure for this sale can be found here. In the last 90 days, insiders sold 308,015 shares of company stock worth $3,088,298. Insiders own 46.50% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in CORI. Bank of New York Mellon Corp boosted its position in Corium International by 118.1% in the 1st quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 13,683 shares in the last quarter. New York State Common Retirement Fund purchased a new stake in Corium International in the 2nd quarter worth approximately $158,000. California State Teachers Retirement System purchased a new stake in Corium International in the 2nd quarter worth approximately $263,000. Teachers Advisors LLC purchased a new stake in Corium International in the 2nd quarter worth approximately $272,000. Finally, TIAA CREF Investment Management LLC purchased a new stake in Corium International in the 2nd quarter worth approximately $411,000. Institutional investors and hedge funds own 90.14% of the company’s stock.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
What are top analysts saying about Corium International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corium International Inc. and related companies.